← All trials
NCT04877210
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2020
- Primary completion
- Aug 1, 2021
- Completion date
- Jan 26, 2022
- First posted
- May 7, 2021
- Last posted
- May 11, 2021
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National University of MalaysiaLead sponsor
- National University of MalaysiaReponsible party - principal investigator
- UKM Medical CentreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.